

## SENATE SUMMARY OF HOUSE AMENDMENTS

SB 27

2018 Regular Session

Mills

**KEYWORD AND SUMMARY AS RETURNED TO THE SENATE**

MEDICAID. Provides for membership of Medicaid Pharmaceutical and Therapeutics Committee. (8/1/18)

**SUMMARY OF HOUSE AMENDMENTS TO THE SENATE BILL**

1. Restores current membership requirements on the committee for the two practicing pharmacists who are participating in the Title XIX drug program.
2. Repeals prohibition in the Medicaid pharmacy program on restricting certain drugs through prior authorization.

**DIGEST OF THE SENATE BILL AS RETURNED TO THE SENATE**

Present law provides for 21 members of the Medicaid Pharmaceutical and Therapeutics Committee. Proposed law reduces the membership to 15 members.

Present law requires that the committee be representative of the state's geographic and demographic composition, including women and minorities. Proposed law requires that the governor ensure race, gender, and geographic diversity in making his appointments.

Present law provides for committee membership nominations by trade associations. Proposed law provides for committee membership nominations by state health profession licensing boards.

Proposed law provides opportunity for replacement of committee members upon absence from two consecutive meetings. Proposed law provides for the department to nominate a replacement member if the nominating organization does not do so within 30 calendar days of notice that its nominee has been removed from the committee.

Proposed law retains provisions in present law that of the two practicing pharmacists participating in the Title XIX drug program, one be an independent pharmacist recommended by the La. Independent Pharmacies Association and one pharmacist be a pharmacist representing a chain pharmacy recommended by the La. Pharmacists Association.

Present law prohibits the Department of Health from restricting by prior authorization any anti-retroviral prescription drug prescribed and determined by a prescribing practitioner licensed by the state to be medically necessary for the treatment and prevention of HIV/AIDS. Provides that anti-retroviral prescription drugs include but are not limited to protease inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, anti-virals, and fusion inhibitors prescribed for the treatment of HIV/AIDS.

Proposed law repeals this provision.

Effective August 1, 2018.

(Amends R.S. 46:153.3(D)(1) and (2); repeals R.S. 46:153.3(C)(1))

---

Thomas L. Tyler  
Deputy Chief of Staff